伴RARG重排的急性髓系白血病的全球研究
该全球合作研究纳入全球29个研究组/机构共34例伴维甲酸受体γ(RARG)重排的急性髓系白血病(AML)患者,明确其临床病理特征、基因组与转录组图谱及结局;患者对全反式维甲酸(ATRA)和/或三氧化二砷(ATO)均无反应,预后差。
要点
- 伴RARG重排的AML形态学与经典急性早幼粒细胞白血病相似,但对ATRA和ATO不敏感。
- 34例患者中位特征包括出血或瘀斑18例(54.5%),形态学诊断M3占73.5%、M3v占26.5%。
- 估计2年累积复发率68.7%、无事件生存率26.7%、总生存率33.5%。
核心结论
- RARG重排是AML的一种新实体,预后差。
研究设计与样本
- 全球合作研究,从全球29个研究组/机构收集伴RARG重排的AML患者,共纳入34例。
- 研究已在中国临床试验注册中心注册(ChiCTR2200055810)。
主要发现
- 出血或瘀斑见于18例(54.5%)患者。
- 形态学诊断为M3和M3v分别占73.5%和26.5%。
- 免疫表型为CD33、CD13和MPO阳性,CD38、CD11b、CD34和HLA-DR阴性。
- 细胞遗传学显示正常核型占38%,t(11;12)占26%。
- RARG伙伴基因多样,包括CPSF6、NUP98、HNRNPc、HNRNPm、PML和NPM1;WT1和NRAS/KRAS突变是常见共突变。
关键数值与推荐
- 34例患者中对ATRA和/或ATO均无反应。
- 诊断后45天内死亡10例(约29%)。
- 末次随访时23例患者已死亡,估计2年累积复发率68.7%、无事件生存率26.7%、总生存率33.5%。
- 基于201例AML患者RNA测序数据的无监督层次聚类显示,81.8%的RARG融合样本聚类在一起,提示为新分子亚型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with retinoic acid receptor γ (RARG) rearrangement has clinical, morphologic, and immunophenotypic features similar to classic acute promyelocytic leukemia. However, AML with RARG rearrangement is insensitive to alltrans retinoic acid (ATRA) and arsenic trioxide (ATO) and carries a poor prognosis. We initiated a global cooperative study to define the clinicopathological features, genomic and transcriptomic landscape, and outcomes of AML with RARG rearrangements collected from 29 study groups/institutions worldwide. Thirty-four patients with AML with RARG rearrangements were identified. Bleeding or ecchymosis was present in 18 (54.5%) patients. Morphology diagnosed as M3 and M3v accounted for 73.5% and 26.5% of the cases, respectively. Immunophenotyping showed the following characteristics: positive for CD33, CD13, and MPO but negative for CD38, CD11b, CD34, and HLA-DR. Cytogenetics showed normal karyotype in 38% and t(11;12) in 26% of patients. The partner genes of RARG were diverse and included CPSF6, NUP98, HNRNPc, HNRNPm, PML, and NPM1. WT1- and NRAS/KRAS-mutations were common comutations. None of the 34 patients responded to ATRA and/or ATO. Death within 45 days from diagnosis occurred in 10 patients (∼29%). At the last follow-up, 23 patients had died, and the estimated 2-year cumulative incidence of relapse, event-free survival, and overall survival were 68.7%, 26.7%, and 33.5%, respectively. Unsupervised hierarchical clustering using RNA sequencing data from 201 patients with AML showed that 81.8% of the RARG fusion samples clustered together, suggesting a new molecular subtype. RARG rearrangement is a novel entity of AML that confers a poor prognosis. This study is registered with the Chinese Clinical Trial Registry (ChiCTR2200055810).
引用
- Zhu HH, Qin YZ, Zhang ZL, et al. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv. 2023. PMID: 36799929. doi:10.1182/bloodadvances.2022008364
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。